title: The effect of preoperative local interleukin-2 (IL-2) injections in patients with head and neck squamous cell carcinoma. An immunological study.
abstract: Clinical, immunological, immunophenotypical, pathological and molecular biological studies were performed on tumor infiltrating lymphocytes (TIL) and lymph node lymphocytes (LN-ly) of 8 patients with squamous cell carcinoma of the oral cavity and oropharynx treated with 10 daily locoregional injections of low doses of IL-2 before surgery. No complications were seen during or after surgery. In 3 cases the LN-ly showed a moderate LAK activity, higher in the LN-ly omolateral to the tumor and near the IL-2 injection site; in 2 of these 3 patients a good LAK activity was induced after 6-day culture with IL-2. The LN-ly derived from nodes next to the tumor showed a decreased NK activity and proliferative ability both in basal conditions and after in vitro lymphokine challenging. LN-ly of 2 IL-2 treated patients showed high levels of mRNA encoding for IL-2-R, while it was absent in 2 untreated cases. Immunophenotypical studies on TIL showed statistically improved levels of CD25+ and LAK1+ cells in treated cases. Clusters of CD11c+ (macrophages) cells were seen close to the neoplastic sheets.
authors.affiliation: E.N.T. Department, University of Torino, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Cortesina
authors.forename: A
authors.initials: A
authors.lastname: De Stefani
authors.forename: E
authors.initials: E
authors.lastname: Galeazzi
authors.forename: M
authors.initials: M
authors.lastname: Bussi
authors.forename: C
authors.initials: C
authors.lastname: Giordano
authors.forename: G P
authors.initials: GP
authors.lastname: Cavallo
authors.forename: C
authors.initials: C
authors.lastname: Jemma
authors.forename: S
authors.initials: S
authors.lastname: Vai
authors.forename: G
authors.initials: G
authors.lastname: Forni
authors.forename: G
authors.initials: G
authors.lastname: Valente
mesh_terms: D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000502:physiology; D007694:Killer Cells, Natural / Q000502:physiology; D008198:Lymph Nodes / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D010865:Pilot Projects; D011292:Premedication; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D015703:Antigens, CD; D007376:Interleukin-2; D011994:Recombinant Proteins